Tests an NMDA enhancer in adults with depression who did not respond to antidepressants
Tests an NMDA enhancer drug in adults with depression not helped by antidepressants.
Plain-language title generated from the registry record
Registry title: NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
Key facts
- Where
- Taichung, TaiwanSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT05136755, who can take part
Where in Taiwan
- Department of Psychiatry, China Medical University HospitalTaichung, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China Medical University Hospital
- Trial code
- NCT05136755
- Record updated
- 23 October 2026
- Original description
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of antidepressant nonresponders with MDD.Read full original descriptionShow less
NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of antidepressant nonresponders with MDD.
Inclusion: Have a DSM-5 (American Psychiatric Association) diagnosis of MDD; Have failed to respond to at least one antidepressant with adequate dosage and treatment duration; Their original treatments should have been unchanged for at least 8 weeks. Some treatment-resistant patients (that is, having failed to respond to at least two different classes of antidepressants) who have started to refuse any antidepressant by themselves due to previous failure experience are also allowed, if they have already been antidepressant-free for at least 2 weeks; 17-item Hamilton Rating Scale for Depression total score ≥ 18; Agree to participate in the study and provide informed consent.
Exclusion: Initiating or stopping formal psychotherapy within six weeks prior to enrollment; A history of previously received electroconvulsive therapy; Current substance abuse or history of substance dependence in the past 6 months; History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study; Bipolar disorder, schizophrenia or other psychotic disorder; Severe cognitive impairment; Moderate-severe suicidal risks; Inability to follow protocol.